Kling Biotherapeutics to Present B-Cell Immortalization and Antibody Optimization at PEGS Europe

Kling Biotherapeutics, a biotechnology firm specializing in antibody-based treatments for cancer and infectious diseases, has announced its participation in the upcoming Annual Protein & Antibody Engineering Summit (PEGS) Europe. The event will take place in Barcelona, Spain, from November 5 to 7, 2024. During the summit, Kling Biotherapeutics will present findings on its innovative B-cell selection and evolution platforms, Kling-Select and Kling-Evolve.

The first poster, titled "Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select," highlights the capabilities of Kling-Select, a proprietary B-cell immortalization platform. This technology is designed to effectively capture and screen B cells, showing significant promise for identifying new therapeutic targets and antibodies. Kling-Select has been successfully applied to B cells from various species, including humans, camelids, rabbits, mice, and non-human primates. The poster also showcases advancements in the platform’s workflow, which enables the discovery of functional monoclonal antibodies from primary B cells in as little as three weeks.

The second poster, "Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells," focuses on the Kling-Evolve platform. This technology facilitates the rapid ex vivo maturation of immortalized human B cells to identify neutralizing antibodies against viral escape variants. Kling-Evolve holds significant potential for swiftly developing countermeasures to address evolving viruses and emerging pandemic threats.

Michael Koslowski, Chief Executive Officer of Kling Biotherapeutics, emphasized the clinical validation and effectiveness of their technology. The company's platform has been instrumental in discovering the fully human Respiratory Syncytial Virus (RSV) neutralizing antibody nirsevimab, marketed as Beyfortus™ by AstraZeneca and Sanofi. By employing an "effective antibody first" discovery approach, Kling's technologies enable the identification of novel antigen targets applicable to both cancer and infectious diseases. Kling Biotherapeutics is well-positioned to develop next-generation antibody-based treatments that offer highly targeted therapies for cancer patients and address global concerns about rapid responses to emerging pandemic threats.

The details of the poster presentations are as follows:
- Poster Title: "Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select"
- Presenter: Casper Marsman, Senior Scientist – B Cell Platform Lead, Kling Biotherapeutics
- Presentation Number: A073

- Poster Title: "Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells"
- Presenter: Alessandra Villa, Director of Discovery Platforms, Kling Biotherapeutics
- Presentation Number: A074

The posters will be displayed in the Exhibit Hall on the following dates and times:
- Tuesday, November 5 from 10:30 to 19:35 CET
- Wednesday, November 6 from 10:30 to 17:15 CET
- Thursday, November 7 from 10:00 to 13:55 CET

Kling Biotherapeutics, headquartered in Amsterdam, Netherlands, is privately held and focused on the discovery and development of novel therapeutic targets and antibodies. The company owns a comprehensive intellectual property portfolio covering its proprietary platforms, Kling-Select and Kling-Evolve. Kling-Select has been validated in identifying novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified neutralizing antibodies for various infectious diseases, including RSV, COVID-19, and Influenza. More recently, Kling-Select has been applied to B cells from cancer patients, yielding a portfolio of novel target-antibody pairs. The unbiased nature of Kling-Select enables the identification of unique targets and epitopes that traditional discovery methods cannot access.

Kling-Evolve accelerates the ex vivo affinity maturation of B cell clones against targets of interest. This technology can rapidly evolve neutralizing antibodies against emerging viral variants or improve the affinity and selectivity of oncology assets. Kling Biotherapeutics is advancing a unique pipeline of oncology and infectious disease programs, including KBA1412, a first-in-class CD9 antibody being explored in blood cancers.

PEGS Europe is the largest protein and antibody engineering event in Europe, recently expanded to include AI/ML, multispecific antibodies, antibody-drug conjugates, and oncology-focused streams.